TRAX — First Tracks Biotherapeutics Inc stock price, charts and financials

QT91First Tracks Biotherapeutics Inc

First Tracks Biotherapeutics Inc (NASDAQ: TRAX) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
38.60
-0.60-1.53%
OverviewShort InterestFilings
TRAXQT91First Tracks Biotherapeutics Inc·NASDAQ
38.60-1.53%
Analyst
Down 1.5% — Evercore ISI initiated coverage at Outperform, price target $65.
Medium confidence
TA
Loading chart...
Screen all →
NKTR-1.84%$67.10RAPP-3.58%$40.45GHRS-1.60%$28.26ZYME-3.31%$26.57MESO+1.75%$15.13AGIO-1.61%$33.07ZBIO-1.47%$31.50RXRX+8.19%$3.83
Snapshot
Index-P/E-EPS (ttm)-Insider Own-Shs Outstand34.89MPerf Week5.93%
Market Cap1.35BForward P/E-EPS next Y-3.78Insider Trans-Shs Float30.22MPerf Month-15.16%
Enterprise Value1.05BPEG-EPS next Q-Inst Own-Short Float13.34%Perf Quarter121.58%
Income-166.00MP/S0.00EPS this Y-Inst Trans-Short Ratio5.29Perf Half Y-
Sales0.00P/B4.69EPS next Y10.34%ROA-45.79%Short Interest4.03MPerf YTD88.20%
Book/sh8.23P/C4.32EPS next 5Y-ROE-39.35%52W High49.91 -22.66%Perf Year-
Cash/sh8.94P/FCF-EPS past 3/5Y-ROIC-50.68%52W Low14.72 162.23%Perf 3Y-
Dividend Est.-EV/EBITDA-Sales past 3/5Y-Gross Margin0.00%Volatility7.06% 7.04%Perf 5Y-
Dividend TTM-EV/Sales0.00EPS Y/Y TTM-Oper. Margin0.00%ATR (14)3.12Perf 10Y-
Dividend Ex-Date-Quick Ratio14.28Sales Y/Y TTM-Profit Margin0.00%RSI (14)44.88Recom2.00
Dividend Gr. 3/5Y-Current Ratio14.28EPS Q/Q-SMA20-6.10%Beta2.74Target Price67.56
Payout0.00%Debt/Eq0.04Sales Q/Q-SMA50-6.91%Rel Volume3.27Prev Close39.20
Employees104LT Debt/Eq0.04EarningsAug 07SMA20031.89%Avg Volume778.63KPrice38.60
IPO DateApr 20, 2026Option/ShortNo / YesEPS/Sales Surpr.-18.37% -Net Debt/EBITDA1.87Volume2,546,414Change-1.53%
Analyst Ratings
DateActionAnalystRatingTarget
Sep-18-26InitiatedEvercore ISIOutperform$65
Sep-16-26InitiatedGuggenheimBuy$100
Aug-13-26ReiteratedPiper Sandler$54 → $95
Aug-13-26ReiteratedH.C. Wainwright$44 → $57
Aug-13-26ReiteratedBarclays$48 → $65
Aug-10-26ReiteratedUBS$45 → $65
Jul-28-26ReiteratedWedbush$30 → $60
Jul-28-26ReiteratedWells Fargo$30 → $55
Jul-21-26ReiteratedBarclays$40 → $48
Jul-10-26ReiteratedH.C. Wainwright$30 → $44
Latest News· Times ET
Sep-16-26
Sep-16-2604:12AM
Guggenheim Initiates Coverage On First Tracks with Buy Rating, Announces Price Target of $100Benzinga
Sep-10-26
Sep-10-2608:52AM
Rosnilimab Emerges as a Potential Advance in Rheumatoid Arthritis as Physicians Look to the Next Wave of Pipeline InnovationYahoo
Sep-07-26
Sep-07-2612:41AM
Insider Selling: First Tracks Biotherapeutics (NASDAQ:TRAX) Director Sells $1,758,286.70 in Stockdefenseworld.net
Sep-02-26
Sep-02-2610:30AM
Which stocks are gapping on Wednesday?ChartMill
Aug-26-26
Aug-26-2612:15PM
First Tracks Biotherapeutics Announces Participation in September Investor Conferencesglobenewswire.com
Aug-13-26
Aug-13-2606:09AM
Barclays Maintains Overweight on First Tracks, Raises Price Target to $65Benzinga
05:07AM
First Tracks Biotherapeutics Analysts Increase Their Forecasts After Q2 Resultsbenzinga.com
Aug-12-26
Aug-12-2612:15PM
First Tracks Biotherapeutics Announces Second Quarter 2026 Financial Results and Provides Business Updateglobenewswire.com
Aug-10-26
Aug-10-2612:16PM
UBS Maintains Buy on First Tracks, Raises Price Target to $65Benzinga
Jul-28-26
Jul-28-2604:51AM
Wedbush Maintains Outperform on First Tracks, Raises Price Target to $60Benzinga
Jul-21-26
Jul-21-2601:05PM
12 Health Care Stocks Moving In Tuesday's After-Market SessionBenzinga
Jul-17-26
Jul-17-2612:35AM
First Tracks Biotherapeutics (NASDAQ:TRAX) Receives Consensus Rating of “Moderate Buy” from Analystsdefenseworld.net
Jul-10-26
Jul-10-2602:13AM
HC Wainwright & Co. Maintains Buy on First Tracks, Raises Price Target to $44Benzinga
Jul-09-26
Jul-09-2603:00PM
Which stocks are experiencing notable movement on Thursday?ChartMill
Jun-11-26
Jun-11-2601:05PM
12 Health Care Stocks Moving In Thursday's After-Market SessionBenzinga
Company

First Tracks Biotherapeutics, Inc., situated in San Diego, California, specializes in pioneering new immunology-based treatments. The firm is actively involved in the discovery and progression of therapeutics aimed at combating autoimmune and inflammatory disorders, currently advancing programs like rosnilimab, ANB033, and ANB101 through their clinical stages.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
Total Revenue
000
Cost of Goods Sold Incl. D&A1401520
Gross Profit-140-1520
Selling, General and Administrative Excl. Other392921
Research and Development14015298
Other Operating Expense-140-152-1
Operating Income-179-181-118
Interest Expense
000
Unusual Expense
———
Non-Operating Income (Expense)131712
Net Income Before Taxes-166-164-106
Income Taxes
000
Consolidated Net Income-166-164-106
Net Income From Continuing Operations-166-164-106
Net Income-166-164-106
EPS (Recurring)0.000.00-3.05
EPS (Basic, Before Extraordinaries)0.000.00-3.05
EPS (Diluted)0.000.00-3.05
EBITDA-178-179-116
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio
———
Gross Margin
———
Operating Margin
———
Net Margin
———
Shares Outstanding353535
Market Capitalization
———
Operating Lease Expense
———
Insider Trading Volume
$52.81$42.22$31.62$21.02$10.43● Close Price0.00K0.00K0.00K0.00K0.00KUSD Trades VolumeSepOctNovDec2026FebMarAprMayJunJulAugSep
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.